Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
ACTIVE NOT RECRUITING
NCT06340048
PHASE1/PHASE2

Epicardial Injection of hiPSC-CMs to Treat Severe Chronic Ischemic Heart Failure

Sponsor: HELP Therapeutics Co., Ltd.

View on ClinicalTrials.gov

Summary

The purpose of this clinical study is to evaluate the feasibility, safety and efficacy of intramyocardial injection of human induce pluripotent stem cell-derived cardiomyocytes (HiCM-188) during coronary artery bypass grafting (CABG) surgery in patients with severe chronic ischemic heart failure.

Official title: Epicardial Injection of Allogeneic Human Pluripotent Stem Cell-derived Cardiomyocytes to Treat Severe Chronic Ischemic Heart Failure

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

36

Start Date

2023-09-05

Completion Date

2027-05-10

Last Updated

2026-02-10

Healthy Volunteers

No

Conditions

Interventions

DRUG

HiCM-188 therapy

Epicardial Injection of Allogeneic Human Pluripotent Stem Cell-derived Cardiomyocytes (HiCM-188) during coronary artery bypass grafting surgery

Locations (1)

TEDA International Cardiovascular Hospital

Tianjin, Tianjin Municipality, China